ArticleOncology and therapy2025
Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway.
Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdequate information about patients with bone metastases could increase adherence to treatment and reduce or delay skeletal and dental complications. Limited data are available on patient awareness, the degree of information received, and adherence to specific treatment for bone metastases.
methodsROPI (Rete Oncologica Pazienti Italia) conducted an anonymous survey from 1 February to 31 August 2022 among patients with bone metastases from solid tumors to evaluate their level of information and adherence to specific treatments and dental evaluations. Questionnaires were administered by oncologists or nurses at participating cancer centers.
resultsAnalysis of 351 questionnaires revealed that 75% of patients felt "fairly/well" informed about bone metastases and skeletal complications. The oncologists were the primary source of information. More than 80% of patients reported undergoing specific treatment for bone metastases (denosumab, 48%; zoledronic acid, 46%); 93% of patients received dental evaluations before starting therapy (with dental complications in only 0.3% of patients) and 78% received information about the importance of regular dental checkups. Vitamin D and calcium supplements were taken by 83% of patients. Among patients with skeletal complications (47% of patients), bone radiotherapy was the most frequent (94%).
conclusionsMost patients stated that they had received information about bone metastases, skeletal complications, and specific treatments. This could increase awareness and adherence to treatment and potentially reduce or delay skeletal and/or dental complications improving patients' quality of life and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.